<DOC>
	<DOC>NCT01066481</DOC>
	<brief_summary>The purpose of this study is to demonstrate the safety and efficacy of PF-01913539 in the treatment of patients with mild-to-moderate Alzheimer's Disease. It is a 6-month study enrolling 651 patients in Japan, Hong Kong, Korea, and Republic of China. All patients completing the 6-month study will be eligible to receive PF-01913539 in an open-label extension trial (B1451031).</brief_summary>
	<brief_title>A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>MildtoModerate Alzheimer's disease MMSE score 1024 inclusive Administration of antidementia drugs including cholinesteraseinhibitors or NMDA receptor antagonists within 90 days Complication of other causes of dementia</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Alzheimer's disease</keyword>
	<keyword>clinical trial</keyword>
	<keyword>memory loss</keyword>
	<keyword>investigational drug</keyword>
	<keyword>neurodegenerative disease</keyword>
	<keyword>dementia</keyword>
</DOC>